Date

 

 

 

Search Results

Showing 1 - 1 of 1
Sort by: Newest first | Best match

MEDICARE ISSUES PROPOSED COVERAGE DECISION ON ERYTHROPOESIS STIMULATING AGENTS

The Centers for Medicare & Medicaid Services (CMS) announced today its proposed decision to limit coverage of erythropoiesis stimulating agent (ESA) treatment for beneficiaries with certain cancers and related neoplastic conditions, either because of a deleterious effect of the ESA on the beneficiaries’ underlying disease or because the underlying disease increases their risk of adverse effects related to ESA use.
Press Release